76712-82-8

76712-82-8 structure

Name: Histrelin
Chemical Name: histrelin
CAS Number: 76712-82-8
Molecular Formula: C₆₆H₈₆N₁₈O₁₂
Molecular Weight: 1323.502
Catalog: Biochemical Peptide
Create Date: 2018-07-06 05:52:10
Modify Date: 2024-01-05 16:33:22
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis[1][2][5].

Name	histrelin
Synonyms	histreline 6-(1-(Phenylmethyl)-D-histidine)-9-(N-ethyl-L-prolinamide)-10-deglycinamideluteinizing hormone-releasing fFactor histrelinum HISTRELIN 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-(phenylmethyl)-D-histidyl-L-leucyl-L-arginyl-N-ethyl- MFCD00133494 histrelina (Des-Gly10,His(Bzl)6,Pro-NHEt9)-LHRH

Description	Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis[1][2][5].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> GNRH Receptor Research Areas >> Cancer
Target	GnRH Receptor[1]
In Vitro	Histrelin (10-100 nM) stimulates the release of vasopressin (VP) from from isolated rat hypothalamo-neurohypophysial explants[4]. Histrelin (100 nM) stimulates oxytocin (OT) release from the rat hypothalamo-neurohypophysial system[5].
In Vivo	Histrelin (0.1 mg/kg, subcutaneous injection) rescues the circulating LH concentrations in Csfmop/Csfmop mice[2]. Histrelin (10,30, or 100 μg /day, subcutaneous injection) reduces the number of endometrial glands and atrophied the stroma in rabbits[3]. Animal Model: Csfmop/Csfmop mice [2] Dosage: 0.001, 0.05, and 0.1 mg/kg Administration: Subcutaneous injection Result: Increased serum FSH concentrations by 4-fold. Animal Model: Rabbits[3] Dosage: 10, 30, or 100 μg /day Administration: Subcutaneous injection for 4 weeks Result: Caused a regression of the endometrial glands and a thinning of the stroma.
References	[1]. Emma D Deeks, et al. Histrelin: in advanced prostate cancer. Drugs. 2010 Mar 26;70(5):623-30. [2]. P E Cohen, et al. Colony-stimulating factor-1 plays a major role in the development of reproductive function in male mice. Mol Endocrinol. 1997 Oct;11(11):1636-50. [3]. D W Hahn, et al. Development of an animal model for quantitatively evaluating effects of drugs on endometriosis. Fertil Steril. 1985 Sep;44(3):410-5. [4]. E Boczek-Leszczyk, et al. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of gonadotrophin-releasing hormone (GnRH), its analogues and melatonin. J Physiol Pharmacol. 2010 Aug;61(4):459-66. [5]. Marlena Juszczak, et al. Hypothalamic gonadotropin-releasing hormone receptor activation stimulates oxytocin release from the rat hypothalamo-neurohypophysial system while melatonin inhibits this process. Brain Res Bull. 2010 Jan 15;81(1):185-90.

Density	1.5±0.1 g/cm3
Boiling Point	1800.6ºC at 760 mmHg
Molecular Formula	C₆₆H₈₆N₁₈O₁₂
Molecular Weight	1323.502
Flash Point	1042.8ºC
Exact Mass	1322.667236
PSA	446.86000
LogP	0.09
Index of Refraction	1.701

CHEMICAL IDENTIFICATION

RTECS NUMBER :: OK6370800

CHEMICAL NAME :: Luteinizing hormone releasing factor (pig), 6-(1-(phenylmethyl)-D-histidine)-9-(N-ethyl-L- prolinamide)-10-deglycinamide-

CAS REGISTRY NUMBER :: 76712-82-8

LAST UPDATED :: 199612

DATA ITEMS CITED :: 3

MOLECULAR FORMULA :: C66-H86-N18-O12

MOLECULAR WEIGHT :: 1323.70

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 46 ug/kg

SEX/DURATION :: male 2 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - other effects on male

REFERENCE :: JOAND3 Journal of Andrology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1980- Volume(issue)/page/year: 7,140,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 4667 ug/kg

SEX/DURATION :: male 8 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

REFERENCE :: JOAND3 Journal of Andrology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1980- Volume(issue)/page/year: 7,140,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2333 ug/kg

SEX/DURATION :: male 4 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

REFERENCE :: JOAND3 Journal of Andrology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1980- Volume(issue)/page/year: 7,140,1986

Symbol	GHS08
Signal Word	Danger
Hazard Statements	H360
Precautionary Statements	P201-P308 + P313
Personal Protective Equipment	Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	T: Toxic;
Risk Phrases	R60
Safety Phrases	53-22-36/37/39-45
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	OK6370800
HS Code	2937190090

HS Code	2937190090

76712-82-8	220810-26-4
321709-40-4	134190-11-7
134009-09-9	90760-96-6
134053-51-3	321709-43-7
1158522-08-7	1240527-38-1
1269036-78-3	922043-35-4
1087647-03-7	940364-43-2
863445-01-6	921825-98-1
134104-43-1	921806-05-5